menu
    • menu
    [{"orgOrder":0,"company":"Yale University","sponsor":"CSL Behring","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Fibrinogen","moa":"Fibrinogen","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I\/ Phase II","graph3":"Yale University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Solution","sponsorNew":"Yale University \/ CSL Behring","highestDevelopmentStatusID":"7","companyTruncated":"Yale University \/ CSL Behring"},{"orgOrder":0,"company":"Duke University","sponsor":"CSL Behring","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Fibrinogen","moa":"Fibrinogen","graph1":"Hematology","graph2":"Phase IV","graph3":"Duke University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Duke University \/ CSL Behring","highestDevelopmentStatusID":"11","companyTruncated":"Duke University \/ CSL Behring"},{"orgOrder":0,"company":"Rigshospitalet","sponsor":"CSL Behring","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"DENMARK","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Fibrinogen","moa":"Fibrinogen","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Rigshospitalet","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rigshospitalet \/ CSL Behring","highestDevelopmentStatusID":"8","companyTruncated":"Rigshospitalet \/ CSL Behring"},{"orgOrder":0,"company":"Copenhagen University Hospital at Herlev","sponsor":"Rigshospitalet | Copenhagen University Hospital, Hvidovre | Hillerod Hospital, Denmark | Blood Bank of the Danish Capital Region | Unit for Monitoring of Good Clinical Practice, Copenhagen University | Danish Council for Independent Research | Herlev Hosp","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"DENMARK","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Fibrinogen","moa":"Fibrinogen","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II\/ Phase III","graph3":"Copenhagen University Hospital at Herlev","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Copenhagen University Hospital at Herlev \/ Rigshospitalet | Copenhagen University Hospital, Hvidovre | Hillerod Hospital, Denmark | Blood Bank of the Danish Capital Region | Unit for Monitoring of Good Clinical Practice, Copenhagen University | Danish Council for Independent Research | Herlev Hosp","highestDevelopmentStatusID":"9","companyTruncated":"Copenhagen University Hospital at Herlev \/ Rigshospitalet | Copenhagen University Hospital, Hvidovre | Hillerod Hospital, Denmark | Blood Bank of the Danish Capital Region | Unit for Monitoring of Good Clinical Practice, Copenhagen University | Danish Council for Independent Research | Herlev Hosp"},{"orgOrder":0,"company":"IRCCS Policlinico S. Donato","sponsor":"CSL Behring","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ITALY","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Fibrinogen","moa":"Fibrinogen","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"IRCCS Policlinico S. Donato","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IRCCS Policlinico S. Donato \/ CSL Behring","highestDevelopmentStatusID":"10","companyTruncated":"IRCCS Policlinico S. Donato \/ CSL Behring"},{"orgOrder":0,"company":"Grifols International","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SPAIN","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Fibrinogen","moa":"Fibrinogen","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Grifols International \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Undisclosed"},{"orgOrder":0,"company":"Octapharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Fibrinogen","moa":"Fibrinogen","graph1":"Hematology","graph2":"Approved FDF","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Octapharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Octapharma \/ Undisclosed"},{"orgOrder":0,"company":"Octapharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Fibrinogen","moa":"Fibrinogen","graph1":"Hematology","graph2":"Phase III","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Octapharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Octapharma \/ Undisclosed"},{"orgOrder":0,"company":"Biotest","sponsor":"Icon Plc | SGS Life Sciences | Phoenix Clinical Research | Accovion | Pharmetheus AB","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"GERMANY","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Fibrinogen","moa":"Fibrinogen","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Biotest","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biotest \/ Icon Plc | SGS Life Sciences | Phoenix Clinical Research | Accovion | Pharmetheus AB","highestDevelopmentStatusID":"10","companyTruncated":"Biotest \/ Icon Plc | SGS Life Sciences | Phoenix Clinical Research | Accovion | Pharmetheus AB"},{"orgOrder":0,"company":"Octapharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Fibrinogen","moa":"Fibrinogen","graph1":"Hematology","graph2":"Approved FDF","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Octapharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Octapharma \/ Undisclosed"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Fibrinogen","moa":"Fibrinogen","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sunnybrook Health Sciences Centre \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sunnybrook Health Sciences Centre \/ Undisclosed"},{"orgOrder":0,"company":"University Health Network, Toronto","sponsor":"Sunnybrook Health Sciences Centre | Octapharma | Canadian Institutes of Health Research | Canadian Institute for Military and Veteran Health Research Defense Research & Development Canada","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CANADA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Fibrinogen","moa":"Fibrinogen","graph1":"Hematology","graph2":"Phase IV","graph3":"University Health Network, Toronto","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Solution","sponsorNew":"University Health Network, Toronto \/ Sunnybrook Health Sciences Centre | Octapharma | Canadian Institutes of Health Research | Canadian Institute for Military and Veteran Health Research Defense Research & Development Canada","highestDevelopmentStatusID":"11","companyTruncated":"University Health Network, Toronto \/ Sunnybrook Health Sciences Centre | Octapharma | Canadian Institutes of Health Research | Canadian Institute for Military and Veteran Health Research Defense Research & Development Canada"},{"orgOrder":0,"company":"University of Virginia","sponsor":"Octapharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Fibrinogen","moa":"Fibrinogen","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"University of Virginia","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Virginia \/ Octapharma","highestDevelopmentStatusID":"11","companyTruncated":"University of Virginia \/ Octapharma"},{"orgOrder":0,"company":"Nova Scotia Health Authority","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Fibrinogen","moa":"Fibrinogen","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Nova Scotia Health Authority","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nova Scotia Health Authority \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nova Scotia Health Authority \/ Undisclosed"},{"orgOrder":0,"company":"University of Sao Paulo","sponsor":"CSL Behring","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"BRAZIL","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Fibrinogen","moa":"Fibrinogen","graph1":"Hematology","graph2":"Phase II","graph3":"University of Sao Paulo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Sao Paulo \/ CSL Behring","highestDevelopmentStatusID":"8","companyTruncated":"University of Sao Paulo \/ CSL Behring"}]

    Find Clinical Drug Pipeline Developments & Deals for Fibrinogen

    Menu

    Fibrinogen

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Octapharma

                            Switzerland arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Octapharma

                            Switzerland arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fibrinogen

                            Therapeutic Area : Hematology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Approves Fibryga® for Fibrinogen Supplementation in Acquired Deficiency

                            Details : Fibryga is a fibrinogen concentrate which acts as as fibrinogen replacement therapy. It is approved for the treatment of acquired fibrinogen deficiency (AFD).

                            Product Name : Fibryga

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            August 01, 2024

                            Lead Product(s) : Fibrinogen

                            Therapeutic Area : Hematology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Octapharma

                            Switzerland arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Octapharma

                            Switzerland arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fibrinogen

                            Therapeutic Area : Hematology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Approvals Strengthen Octapharma USA Pediatric Critical Care Product Portfolio

                            Details : The supplement approvals resulted in new product labeling for Octaplas™, Pooled Plasma (Human), Solvent/Detergent (S/D) Treated Solution for Intravenous Infusion, and fibryga®, Fibrinogen (Human) Lyophilized Powder for Reconstitution.

                            Product Name : Fibryga

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            March 29, 2021

                            Lead Product(s) : Fibrinogen

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Octapharma

                            Switzerland arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Octapharma

                            Switzerland arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fibrinogen

                            Therapeutic Area : Hematology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Octapharma USA Presents Research on Congenital & Acquired Bleeding Disorders at ASH Annual Meeting

                            Details : Octapharma to present multiple clinical trial posters on the efficacy and safety of fibryga®, Fibrinogen (Human) Lyophilized Powder for Reconstitution, for Intravenous Use to treat congenital and acquired bleeding disorders.

                            Product Name : Fibryga

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            December 03, 2020

                            Lead Product(s) : Fibrinogen

                            Therapeutic Area : Hematology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Grifols International

                            Spain arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Grifols International

                            Spain arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fibrinogen

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FIB Grifols Congenital Deficiency for On-demand Treatment and Surgical Prophylaxis

                            Details : Fibrinogen is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Afibrinogenemia.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            November 19, 2020

                            Lead Product(s) : Fibrinogen

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            University Health Network, Toronto

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            University Health Network, Toronto

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fibrinogen

                            Therapeutic Area : Hematology

                            Study Phase : Phase IV

                            Sponsor : Sunnybrook Health Sciences Centre | Octapharma | Canadian Institutes of Health Research | Canadian Institute for Military and Veteran Health Research Defense Research & Development Canada

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Factor In the Initial Resuscitation of Severe Trauma 2 Patients

                            Details : Fibrinogen is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hemorrhage.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            September 01, 2020

                            Lead Product(s) : Fibrinogen

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase IV

                            Sponsor : Sunnybrook Health Sciences Centre | Octapharma | Canadian Institutes of Health Research | Canadian Institute for Military and Veteran Health Research Defense Research & Development Canada

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            University of Virginia

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            University of Virginia

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fibrinogen

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase IV

                            Sponsor : Octapharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparison of Fibrinogen Concentrate and Cryoprecipitate in Pediatric Cardiac Surgery Patients

                            Details : Fibrinogen is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Huntington Disease.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            May 06, 2020

                            Lead Product(s) : Fibrinogen

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase IV

                            Sponsor : Octapharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Yale University

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Yale University

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fibrinogen

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase I/ Phase II

                            Sponsor : CSL Behring

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Program to Evaluate Riastap® and FIBTEM® for the Early Control and Treatment of Postpartum Hemorrhage ...

                            Details : Riastap (Fibrinogen) is a Protein drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Postpartum Hemorrhage.

                            Product Name : Riastap

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            August 19, 2015

                            Lead Product(s) : Fibrinogen

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : CSL Behring

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Rigshospitalet

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Rigshospitalet

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fibrinogen

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase II

                            Sponsor : CSL Behring

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pilot Randomized Trial of Fibrinogen in Trauma Haemorrhage

                            Details : Fibrinogen is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Wounds and Injuries.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            January 22, 2015

                            Lead Product(s) : Fibrinogen

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase II

                            Sponsor : CSL Behring

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Sunnybrook Health Sciences Centre

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Sunnybrook Health Sciences Centre

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fibrinogen

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Fibrinogen in the Initial Resuscitation of Severe Trauma (FiiRST)

                            Details : Fibrinogen is a Protein drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Wounds and Injuries.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            July 30, 2014

                            Lead Product(s) : Fibrinogen

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Biotest

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Biotest

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fibrinogen

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase III

                            Sponsor : Icon Plc | SGS Life Sciences | Phoenix Clinical Research | Accovion | Pharmetheus AB

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacokinetic, Efficacy and Safety of BT524 in Patients With Congenital Fibrinogen Deficiency

                            Details : Fibrinogen is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Afibrinogenemia.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            February 19, 2014

                            Lead Product(s) : Fibrinogen

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase III

                            Sponsor : Icon Plc | SGS Life Sciences | Phoenix Clinical Research | Accovion | Pharmetheus AB

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth